首页 | 本学科首页   官方微博 | 高级检索  
检索        

一次性静脉注射高剂量链脲佐菌素建立1型糖尿病小型猪模型
引用本文:崔永春,李凯,张宏,刘晓鹏,袁卫民,李巨波,吴爱丽,唐跃.一次性静脉注射高剂量链脲佐菌素建立1型糖尿病小型猪模型[J].实验动物与比较医学,2014,22(4):12-15.
作者姓名:崔永春  李凯  张宏  刘晓鹏  袁卫民  李巨波  吴爱丽  唐跃
作者单位:中国医学科学院北京协和医学院国家心血管病中心, 阜外心血管病医院动物实验中心, 心血管疾病国家重点实验室, 北京市心血管植入材料临床前评价重点实验室, 北京 100037;中国医学科学院北京协和医学院国家心血管病中心, 阜外心血管病医院动物实验中心, 心血管疾病国家重点实验室, 北京市心血管植入材料临床前评价重点实验室, 北京 100037;中国医学科学院北京协和医学院国家心血管病中心, 阜外心血管病医院动物实验中心, 心血管疾病国家重点实验室, 北京市心血管植入材料临床前评价重点实验室, 北京 100037;中国医学科学院北京协和医学院国家心血管病中心, 阜外心血管病医院动物实验中心, 心血管疾病国家重点实验室, 北京市心血管植入材料临床前评价重点实验室, 北京 100037;中国医学科学院北京协和医学院国家心血管病中心, 阜外心血管病医院动物实验中心, 心血管疾病国家重点实验室, 北京市心血管植入材料临床前评价重点实验室, 北京 100037;中国医学科学院北京协和医学院国家心血管病中心, 阜外心血管病医院动物实验中心, 心血管疾病国家重点实验室, 北京市心血管植入材料临床前评价重点实验室, 北京 100037;中国医学科学院北京协和医学院国家心血管病中心, 阜外心血管病医院动物实验中心, 心血管疾病国家重点实验室, 北京市心血管植入材料临床前评价重点实验室, 北京 100037;中国医学科学院北京协和医学院国家心血管病中心, 阜外心血管病医院动物实验中心, 心血管疾病国家重点实验室, 北京市心血管植入材料临床前评价重点实验室, 北京 100037
基金项目:北京市科委科技计划“常见心脑血管缺血性疾病模型研发公共平台建设”(Z101107052210004)基金;协和青年基金“糖尿病小型猪急性心肌缺血代谢组学研究(2012-XHQN04)支持。
摘    要:目的 探讨通过一次性注射高剂量链脲佐菌素(streptozotocin,STZ)方法建立1型糖尿病小型猪模型的可行性。方法 中华实验小型猪耳缘静脉一次性注射链脲佐菌素溶液150 mg/kg,分别在给药前和给药后10 min、30 min、90 min、第1天、第2天、第3天和第7天空腹采集静脉血,动态监测空腹血糖,并利用静脉糖耐量实验和C肽释放实验对模型进行鉴定。结果 给药后第1天开始,模型组空腹血糖明显升高并始终维持在16.7~20.6 mmol/L的浓度范围,达到糖尿病标准;静脉葡萄糖耐量试验和C肽释放实验结果表明,静脉注射体积分数50%的葡萄糖1 h后模型猪血糖浓度高于11.1 mmol/L,2 h后未能恢复至空腹血糖水平;而胰岛素和C肽在注入葡萄糖后基本未发生任何反应,始终保持痕量水平。结论 一次性静脉注射大剂量链脲佐菌素的方法能够成功建立1型糖尿病小型猪模型。

关 键 词:1型糖尿病  小型猪  链脲佐菌素  血糖
收稿时间:2014/4/11 0:00:00
修稿时间:2013/12/12 0:00:00

Establishment of a miniature pig model of type 1 diabetes by single intravenous injection of high dose streptozotocin
CUI Yong-chun,LI Kai,ZHANG Hong,LIU Xiao-peng,YUAN Wei-min,LI Ju-bo,WU Ai-li and TANG Yue.Establishment of a miniature pig model of type 1 diabetes by single intravenous injection of high dose streptozotocin[J].Laboratory Animal and Comparative Medicine,2014,22(4):12-15.
Authors:CUI Yong-chun  LI Kai  ZHANG Hong  LIU Xiao-peng  YUAN Wei-min  LI Ju-bo  WU Ai-li and TANG Yue
Institution:State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing Municipal Key Laboratory for Pre-clinical Evaluation of Cardiovascular Implantation Devices, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing Municipal Key Laboratory for Pre-clinical Evaluation of Cardiovascular Implantation Devices, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing Municipal Key Laboratory for Pre-clinical Evaluation of Cardiovascular Implantation Devices, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing Municipal Key Laboratory for Pre-clinical Evaluation of Cardiovascular Implantation Devices, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing Municipal Key Laboratory for Pre-clinical Evaluation of Cardiovascular Implantation Devices, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing Municipal Key Laboratory for Pre-clinical Evaluation of Cardiovascular Implantation Devices, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing Municipal Key Laboratory for Pre-clinical Evaluation of Cardiovascular Implantation Devices, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing Municipal Key Laboratory for Pre-clinical Evaluation of Cardiovascular Implantation Devices, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
Abstract:Objective To explore the feasibility of establishing mini-pig model of type 1 diabetes by single intravenous injection of high dose streptozotocin. Methods Eight male Zhonghua mini-pigs (22.6±1.8 kg) were administrated with high-dose streptozotocin (150 mg/kg) into the ear vein. Before and 10, 30, 90 minutes, 1, 3 and 7 days after administration of streptozotocin, blood samples were obtained respectively, and used to dynamically monitor the fasting blood-glucose. C peptide and insulin levels were evaluated by IVGTT test. Results Since 24 hours after STZ administration, the fasting blood-glucose level was increased significantly compared with that of pre-administration and maintained at 16.7-20.6 mmol/L, while the C peptide and insulin levels were decreased significantly. IVGTT results showed that blood sugar levels at 1 h after intravenous injection of 50% glucose were much higher than 11.1 mmol/L and failed to restore to fasting glucose levels until 2 h, insulin and c-peptide did no response after injection of glucose, always kept at a trace level. Conclusion A single high-dose streptozotocin injection can be used to establish a mini-pig model of type 1 diabetes successfully.
Keywords:Type 1 diabetes  Mini-pig  Streptozotocin  Blood glucose
点击此处可从《实验动物与比较医学》浏览原始摘要信息
点击此处可从《实验动物与比较医学》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号